Table 1 Patients with different risk classification according to 2017 ELN and 2022 ELN.
N | (%) | Molecular features | 2017 ELN risk classification | 2022 ELN risk classification |
|---|---|---|---|---|
20 | 3.7 | Mutated NPM1 with low allelic ratio FLT3-ITD | Favorable | Intermediate |
1 | 0.2 | Biallellic mutated CEBPA (not bZIP domain) + mutated MDS genes | Favorable | Adverse |
4 | 0.7 | bZIP in frame mutated CEBPA (only one CEBPA mutation) | Intermediate | Favorable |
47 | 8.6 | Mutated MDS genes (not RUNX1 and ASXL1) | Intermediate | Adverse |
4 | 0.7 | High allelic ratio FLT3-ITD | Adverse | Intermediate |
1 | 0.2 | Hyperdiploid karyotype + high allelic ratio FLT3-ITD | Adverse | Intermediate |
2 | 0.4 | Hyperdiploid karyotype | Adverse | Intermediate |
